Drug intelligence / Profile preview

BM002

Development stage: Preclinical
Lead developer: BIMINI Biotech
Modality: Small Molecules

Overview

BM002 is a preclinical-stage small molecule therapeutic candidate being developed by BIMINI Biotech. It functions as a second-generation antagonist of the Growth Hormone Receptor (GHR). The drug is part of a pipeline focused on leveraging GHR inhibition to treat various cancers and potentially other growth-related disorders. While the company's lead candidate, BM001, is targeted at solid tumors, the specific primary indication for BM002 has not yet been disclosed and is currently listed as to be determined.

Targets

GHR (Growth hormone receptor)

Beyond the preview

Go deeper on BM002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BM002.

Explore the full profile